Ranbaxy Laboratories Limited will market a fixed dose combination of fenofibrate micronized 160 mg and Atorvastatin 10mg in the domestic market under an in-licensing agreement with Ethypharm LL India (Ethypharm), a wholly-owned subsidiary of a leading French drug delivery company.
Ranbaxy will market the product under its brand name Storfib. The drug will address the need for effective management of mixed dyslipidemia, which is very common amongst the Indian population, Ranbaxy said in a filing with the BSE.
The product will be manufactured by Ethypharm at its facility near Mumbai.
"Ranbaxy in India, is the leader in novel drug delivery system (NDDS) and a pioneer in the lipids management portfolio. The launch of Storfib, which symbolises both these strengths, would further augment our leadership position in the cardio-vascular market," said Sanjeev I Dani, regional director, India and Middle East, Ranbaxy.
Combinational products are growing very fast in India and it is estimated that more than two thirds of all combination products worldwide are registered first in India. Ethypharm endeavours to ensure that the benefits of its drug delivery technologies also encompass such combinational products.
"This product encapsulates the benefits of both combination offerings and drug delivery technologies and will help the large Indian populace who suffer from combined (mixed) dyslipidemia which is common culprit in Asian subcontinent including India", said Ajey Kumar, chief executive officer of Ethypharm India.
Fenofibrate is a drug prescribed to lower triglycerides in cases of Hyperlipidemia while Atorvastatin is a cholesterol lowering drug. Ethypharm's enhanced absorption technologies serve to increase bioavailability of drugs like Fenofibrate thereby making it more efficacious, effective and safe medicine.
Ranbaxy had entered into a similar agreement with Ethypharm, in May this year, for marketing Tramadol Flashtab, a pain management drug.
Ethypharm is present on the principal world health markets with manufacturing and R & D sites in Europe, North America, China and India. The company has a special focus on pain management, cardiovascular, oncology and CNS branded and generic products. Over the years, Ethypharm has developed more than 50 branded and generic products, based on its core proprietary technologies.
Ranbaxy Laboratories, is an integrated, research-based, international pharmaceutical company producing a wide range of quality, affordable generic medicines. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in new drug discovery research.
The company's entry into novel drug delivery systems has led to proprietary "platform technologies", resulting in a number of products under development. The company serves customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries.